Neos Therapeutics, a Dallas-area maker of extended-release formulations for ADHD that disintegrate in the mouth, announced that it aims to raise $60 million on the Nasdaq in an IPO planned for next ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback